Scenic Biotech Joins MJFF's LITE for Lysosomal Parkinson's Push

Scenic Biotech will test its PLA2G15 inhibitor program in Parkinson's disease under the Michael J. Fox Foundation's LRRK2 Investigative Therapeutics Exchange. The collaboration uses preclinical models at the University of Dundee to generate translational data, with Scenic's lead asset SC6177 targeting lysosomal dysfunction across genetic and age-related neurodegeneration.

The mechanism centers on PLA2G15, a lysosomal phospholipase that degrades BMP, a lipid regulating glucocerebrosidase (GBA1) activity. GBA1 mutations are the most common genetic risk factor for Parkinson's. Scenic's brain-penetrant small-molecule inhibitors are designed to raise endogenous BMP levels and restore lysosomal function. The company discovered PLA2G15 through its Cell-Seq functional genomics platform.

"One of LITE's core objectives is to accelerate and streamline the evaluation of promising therapeutic strategies connected to LRRK2 biology," said Shalini Padmanabhan, senior vice president of discovery and translational research at MJFF. "Scenic offers a unique perspective on LRRK2-related mechanisms, focusing on lysosomal health and lipid metabolism."

Scenic CSO Roland Bűrli said joining LITE is an important step as the company expands the PLA2G15 program beyond rare diseases. "With growing evidence that lysosomal dysfunction is believed to play a role in Parkinson's, we will combine our first-in-class approach with LITE's LRRK2 expertise, biomarker infrastructure, and leading academic models."

The initial work will use validated preclinical models developed at the University of Dundee's MRC Protein Phosphorylation Unit. Director Dario Alessi said the PLA2G15-BMP axis offers a compelling way to explore how lysosomal biology intersects with LRRK2-linked Parkinson's disease.

Scenic's pipeline includes SC6177, a neurometabolic asset with candidate selection complete and IND-enabling studies underway. First-in-human trials are targeted for 2027. The company also sees therapeutic potential across Batten disease, Niemann Pick Type C, Alzheimer's, and frontotemporal dementia.

What would confirm the hypothesis Translational data from the Dundee models showing that PLA2G15 inhibition raises BMP levels in relevant cell types or animal models of LRRK2 or GBA1 dysfunction would be the first concrete proof. Follow-on biomarker evidence in cerebrospinal fluid from future clinical trials would strengthen the link between lysosomal restoration and clinical endpoints. Any signal of target engagement from the planned SC6177 first-in-human study would be a second major milestone.

What would weaken the case If preclinical models fail to show BMP elevation or functional improvement in lysosomal health despite brain-penetrant inhibition, the therapeutic reach may be narrower than Scenic expects. Competition from other lysosomal-protective approaches in the MJFF pipeline could also diminish the program's differentiation. The LITE collaboration is non-exclusive, so Scenic must show its mechanism works in a way direct LRRK2 inhibitors cannot.

Next catalysts Scenic's leadership will attend the BIO International Convention in San Diego from June 22-25, 2026, available for investor and partner meetings. IND-enabling work for SC6177 continues toward the 2027 first-in-human target. Additional preclinical data from the LITE collaboration could surface at scientific meetings later this year or in 2027.